a comparison on effects of high dose rosuvastatin versus high dose atorvastatin on lipid profile and crp level in patients undergoing percutaneous coronary intervention: a randomized study

Background: statins are the most common drugs used for reducing low-density lipids (ldl). in addition to their lipid-lowering effects, they have well-documented anti-inflammatory actions. the goal of this study was to compare the effects of high dose atorvastatin and rosuvastatin on lipid profiles and high sensitivity c reactive protein (hs-crp) in patients undergoing percutaneous coronary intervention (pci). methods: the study was done between october 2017 and september 2018 in semnan kowsar hospital. in this randomized trial, 69 patients with atherosclerotic coronary artery disease were randomly assigned 1:1 to receive atorvastatin (80 mg daily) or rosuvastatin (40 mg daily) for 4 months. levels of hs-crp and lipid profiles including cholesterol, triglyceride, low-density lipids (ldl), and high-density lipids (hdl) were measured and compared before and after the treatments. lipid profiles were measured at baseline, 2 months, and 4 months of the treatment. results: sixty patients completed the study. the mean age was 61.1 ± 6.6 years with an excess of males. after 4 months, both drugs could significantly reduce ldl levels, however, the betweengroup differences were not statistically significant. rosuvastatin significantly increased hdl levels (p < 0.05). in addition, triglyceride levels had a significant reduction in both groups, yet the differences were not significant. both drugs caused significant reductions in hs-crp levels (p < 0.05). moreover, the effects of treatments were seen in drug naïve patients as well as patients who were on statins prior to the trial. conclusion: the results indicate that high dose therapies with atorvastatin and rosuvastatin have similar effects on lipid profiles and hs-crp levels in patients undergoing pci.